1238539-07-5Relevant academic research and scientific papers
N - acyl - [...] P 2X7 adjustment
-
Paragraph 0404-0406, (2017/10/28)
The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: These compounds are suitable for use in the treatment of diseases associated with P2X7 receptor activity such as diseases of the autoimmune
Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain
Chrovian, Christa C.,Soyode-Johnson, Akinola,Ao, Hong,Bacani, Genesis M.,Carruthers, Nicholas I.,Lord, Brian,Nguyen, Leslie,Rech, Jason C.,Wang, Qi,Bhattacharya, Anindya,Letavic, Michael A.
, p. 490 - 497 (2016/05/19)
Novel 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists were optimized to allow for good blood-brain barrier permeability and high P2X7 target engagement in the brain of rats. Compound 25 (huP2X7 IC50 = 9 nM; rat P2X7 IC50
Preparation of α,ωtelechelic hexyl acrylate polymers with -OH, -COOH, and -NH2 functional groups by RAFT
Cortez-Lemus, Norma A.,Salgado-Rodriguez, Rodolfo,Licea-Claverie, Angel
experimental part, p. 3033 - 3051 (2011/04/15)
The design, synthesis, and use of two new, stable, functionalzed chain transfer agents (CTA's) containing OH and amine end groups for the RAFT polymerization is reported: 2-hydroxyethoxy-carbonylphenylmethyl dithiobenzoate and 2-(2-(tert-butoxycarbonyl)et
